- Home
- LRMR vs IVA Comparison
LRMR vs IVA Comparison
Compare LRMR & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- IVA
- Stock Information
- Founded
- LRMR N/A
- IVA 2011
- Country
- LRMR United States
- IVA France
- Employees
- LRMR N/A
- IVA N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- LRMR Health Care
- IVA Health Care
- Exchange
- LRMR Nasdaq
- IVA Nasdaq
- Market Cap
- LRMR 309.8M
- IVA 359.6M
- IPO Year
- LRMR N/A
- IVA 2020
- Fundamental
- Price
- LRMR $3.89
- IVA $5.43
- Analyst Decision
- LRMR Strong Buy
- IVA Strong Buy
- Analyst Count
- LRMR 8
- IVA 6
- Target Price
- LRMR $17.88
- IVA $15.33
- AVG Volume (30 Days)
- LRMR 1.4M
- IVA 71.1K
- Earning Date
- LRMR 10-29-2025
- IVA 09-26-2025
- Dividend Yield
- LRMR N/A
- IVA N/A
- EPS Growth
- LRMR N/A
- IVA N/A
- EPS
- LRMR N/A
- IVA N/A
- Revenue
- LRMR N/A
- IVA $14,591,573.00
- Revenue This Year
- LRMR N/A
- IVA $80.35
- Revenue Next Year
- LRMR N/A
- IVA N/A
- P/E Ratio
- LRMR N/A
- IVA N/A
- Revenue Growth
- LRMR N/A
- IVA N/A
- 52 Week Low
- LRMR $1.61
- IVA $1.53
- 52 Week High
- LRMR $9.50
- IVA $6.50
- Technical
- Relative Strength Index (RSI)
- LRMR 54.32
- IVA 60.33
- Support Level
- LRMR $3.59
- IVA $5.21
- Resistance Level
- LRMR $4.08
- IVA $5.75
- Average True Range (ATR)
- LRMR 0.28
- IVA 0.40
- MACD
- LRMR -0.01
- IVA 0.03
- Stochastic Oscillator
- LRMR 58.33
- IVA 55.25
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.